VANCOUVER, Feb. 21, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, […]
Tag: Neovasc
Micro Interventional Devices, Inc. Reaches Settlement Agreement with Neovasc, Inc.
NEWTOWN, Pa., Feb. 20, 2019 /PRNewswire/ — Micro Interventional Devices, Inc. (“MID”) announced today that it is has entered into a Settlement Agreement with Neovasc, Inc. MID (the “Plaintiffs”) filed a lawsuit in September 2018 in the U.S. District Court for the District of New Jersey including […]
Neovasc Provides Corporate Update
VANCOUVER, Feb. 20, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina, today […]
Pierangeli Clinic Initiates Program Providing Neovasc Reducer™ Procedure to Italian Patients with Refractory Angina
VANCOUVER, Feb. 11, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that […]
Neovasc Announces Renewal of German NUB Status 1 Designation for Neovasc Reducer™ Procedure for Treatment of Refractory Angina
VANCOUVER, Jan. 30, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced […]
Neovasc Receives Approval to Proceed with Phase 2 of TIARA-II Study from Clinical Regulators in Germany and the UK
VANCOUVER, Jan 29, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced […]
Neovasc announces peer reviewed publication in JACC demonstrating objective evidence of improvement in perfusion after Reducer implantation
VANCOUVER, Jan. 23, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today […]
Neovasc Announces Dismissal of Claim brought by Edwards Lifesciences
Neovasc Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency
VANCOUVER, Jan. 14, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX:NVCN) announced today that it has received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the […]
Neovasc Receives Nasdaq Notification Regarding Minimum Market Value Deficiency
VANCOUVER, Jan. 3, 2019 /PRNewswire/ – (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), announced today that it has received written notification (the “Notification Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum market value requirement set […]